文献速递产科母胎医学

孕前糖尿病中血管生成标志物异常与隐匿性胎盘功能障碍及胎儿风险

Abnormal serum soluble fms-like tyrosine kinase 1 and placental growth factor as markers of occult placental dysfunction and fetal risk in pregestational diabetes: a prospective masked cohort study.
PubMed 文献 · Am J Obstet Gynecol · 2026-07-30

发现26%参与者出现早发型PlGF异常(孕中期PlGF<第5百分位),19%出现晚发型sFlt-1/PlGF比值异常(孕晚期>38)。血管生成标志物异常预测不良围产结局的敏感度86%、特异度86%。

要点

  • 孕前糖尿病中约四分之一孕妇出现早发型PlGF异常,近五分之一出现晚发型sFlt-1/PlGF比值异常。
  • 血管生成标志物异常预测早产、子痫前期或紧急剖宫产的敏感度和特异度均为86%。
  • Delphi胎儿生长受限标准敏感度仅7%,血管生成标志物可识别独立于胎儿生长的隐匿性胎盘功能障碍。

核心结论

  • 在孕前糖尿病中,血管生成标志物异常可预测不良围产结局,并提示独立于明显胎儿生长受限的隐匿性胎盘功能障碍。

研究设计与样本

  • 从20至36周每4周采集血样检测sFlt-1和PlGF,样本立即冷冻,产后使用Elecsys检测法分析。

主要发现

  • 早发型异常见于26%(95%CI 17-35)参与者,特征为孕中期PlGF<第5百分位。
  • 晚发型异常见于19%(95%CI 13-28)参与者,特征为孕晚期sFlt-1/PlGF比值>38,中位孕周35.9(IQR 34.9-36.6)周。
  • 血管生成标志物异常预测复合结局(早产、子痫前期或紧急剖宫产)的敏感度86%(95%CI 71-94),特异度86%(95%CI 73-93),阳性预测值82%(95%CI 67-91),阴性预测值89%(95%CI 77-95)。
  • Delphi胎儿生长受限标准敏感度仅7%(95%CI 2-20),在血管生成标志物异常者中仅1/44(2.3%)符合,正常者中3/54(5.6%)符合。
  • 定制出生体重百分位在正常组与早发型异常组相似(中位73 [IQR 40-96] vs 84 [35-96],P=.8),晚发型异常组高于正常组(92 [69-100],校正P=.021)。

关键数值与推荐

  • 早发型异常:孕中期PlGF<第5百分位。
  • 晚发型异常:孕晚期sFlt-1/PlGF比值>38。
  • 复合结局包括早产、子痫前期或紧急剖宫产。

临床怎么用

  • 对孕前糖尿病孕妇可考虑系列血管生成标志物检测作为现有胎儿监测的辅助手段。
  • 血管生成标志物异常可识别常规生长评估未发现的隐匿性胎盘功能障碍高风险者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stillbirth rates in pregestational diabetes remain elevated despite advancements in fetal surveillance. Angiogenic biomarkers may be a useful adjunct to identify occult placental dysfunction and stratify fetal risk independently of fetal size. OBJECTIVE: To determine the gestational age-specific prevalence of angiogenic biomarker abnormalities, placental growth factor and soluble fms-like tyrosine kinase 1/placental growth factor ratio, and their associations with perinatal outcomes in pregestational diabetes. STUDY DESIGN: A masked prospective cohort study was conducted in New Zealand from November 2022 to August 2024, including 40 people with type 1 and 58 people with type 2 diabetes. Blood samples for soluble fms-like tyrosine kinase 1 and placental growth factor were collected at 4-week intervals from 20 to 36 weeks' gestation, immediately frozen, and analyzed postpartum using Elecsys assays. RESULTS: Of note, 2 temporal patterns of angiogenic biomarker abnormalities were identified: early-onset, seen in 26% (95% confidence interval, 17-35) of participants, characterized by a second-trimester placental growth factor <5th percentile; and late-onset, seen in 19% (95% confidence interval, 13-28) of participants, characterized by a third-trimester soluble fms-like tyrosine kinase 1/placental growth factor ratio >38 at a median (interquartile range) of 35.9 (34.9-36.6) weeks' gestation. For a composite outcome of preterm birth, preeclampsia, or emergency cesarean section for intrapartum fetal compromise, abnormal angiogenic biomarkers collectively yielded a sensitivity of 86% (95% confidence interval, 71-94), specificity of 86% (95% confidence interval, 73-93), positive predictive value of 82% (95% confidence interval, 67-91), and negative predictive value of 89% (95% confidence interval, 77-95). In contrast, Delphi fetal growth restriction criteria lacked sensitivity (7% [95% confidence interval, 2-20]), being present in only 1/44 (2.3%) of cases with abnormal angiogenic biomarkers and 3/54 (5.6%) with normal biomarkers. Customized birthweight percentiles were similar between the normal and early-onset abnormality groups (median [interquartile range], 73 [40-96] vs 84 [35-96]) (P=.8) but were higher in the late-onset abnormality group than in the normal group (92 [69-100]) (adjusted P=.021). CONCLUSION: In pregestational diabetes, angiogenic biomarker abnormalities predict adverse perinatal outcomes and signal occult placental dysfunction independently of apparent fetal growth restriction. Evaluation of routine angiogenic biomarker measurement as an adjunct to existing fetal surveillance protocols is warranted.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hughes RCE, Williman JA, Lee G, et al. Abnormal serum soluble fms-like tyrosine kinase 1 and placental growth factor as markers of occult placental dysfunction and fetal risk in pregestational diabetes: a prospective masked cohort study. Am J Obstet Gynecol. 2026. PMID: 42532416. doi:10.1016/j.ajog.2026.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。